| Literature DB >> 33113353 |
Ian H Guldner1, Qingfei Wang1, Lin Yang2, Samantha M Golomb1, Zhuo Zhao2, Jacqueline A Lopez3, Abigail Brunory1, Erin N Howe1, Yizhe Zhang2, Bhavana Palakurthi1, Martin Barron4, Hongyu Gao5, Xiaoling Xuei5, Yunlong Liu5, Jun Li4, Danny Z Chen2, Gary E Landreth6, Siyuan Zhang7.
Abstract
Brain metastasis (br-met) develops in an immunologically unique br-met niche. Central nervous system-native myeloid cells (CNS-myeloids) and bone-marrow-derived myeloid cells (BMDMs) cooperatively regulate brain immunity. The phenotypic heterogeneity and specific roles of these myeloid subsets in shaping the br-met niche to regulate br-met outgrowth have not been fully revealed. Applying multimodal single-cell analyses, we elucidated a heterogeneous but spatially defined CNS-myeloid response during br-met outgrowth. We found Ccr2+ BMDMs minimally influenced br-met while CNS-myeloid promoted br-met outgrowth. Additionally, br-met-associated CNS-myeloid exhibited downregulation of Cx3cr1. Cx3cr1 knockout in CNS-myeloid increased br-met incidence, leading to an enriched interferon response signature and Cxcl10 upregulation. Significantly, neutralization of Cxcl10 reduced br-met, while rCxcl10 increased br-met and recruited VISTAHi PD-L1+ CNS-myeloid to br-met lesions. Inhibiting VISTA- and PD-L1-signaling relieved immune suppression and reduced br-met burden. Our results demonstrate that loss of Cx3cr1 in CNS-myeloid triggers a Cxcl10-mediated vicious cycle, cultivating a br-met-promoting, immune-suppressive niche.Entities:
Keywords: Brain metastasis; T cells; bone marrow-derived myeloid cells; brain immunity; cancer immunology; immune suppression; immune therapy; metastatic niche; microglia; tumor microenvironment
Mesh:
Substances:
Year: 2020 PMID: 33113353 PMCID: PMC7704908 DOI: 10.1016/j.cell.2020.09.064
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582